We’ve announced in our previous posts that GoodReprintPractices.com will be doing some deep dive perspective-giving and analyses. While your eagerly awaiting this wisdom, other really smart people have done their analysis and here are some places to go:
The Life Sciences Legal Update
Hat tips to the Drug and Device Law blog for pointing me this way.
The Pharmaceutical and Biotechnology Update
Of course, if you don’t feel like reading anything (and you have perhaps $1500 or so dollars to spend, $400 or so if your in the government), you can attend DIA’s 21st Annual Conference on Marketing Pharmaceuticals in Time of Change on February 24 and 25. Hosted by Wayne Pines, the agenda is likely to accommodate a good deal of expert discussion on this guidance document.
If I missed anyone (including plaintiffs firms or anyone else with a critical analysis–pro or con). Shoot me a comment with your link or email me at john.murray@goodreprintpractices.com.
John
The Next Post: John’s Struggles With Introductory Sections of FDA’s Guidance Document
The Previous Post: Diversion of Sorts: John discusses social media issues with Pharma Marketing Blog
Comments Down Here
// I Accept Wit, Insight, Disagreement, and American Express.
You can follow any responses to this entry via its RSS comments feed. You may also leave a trackback by clicking this link.